rs373789346
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 1P and 0B. PP3
The NM_000051.4(ATM):c.5189G>A(p.Arg1730Gln) variant causes a missense change. The variant allele was found at a frequency of 0.0000421 in 1,613,370 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R1730L) has been classified as Uncertain significance.
Frequency
Consequence
NM_000051.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.5189G>A | p.Arg1730Gln | missense_variant | 35/63 | ENST00000675843.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ATM | ENST00000675843.1 | c.5189G>A | p.Arg1730Gln | missense_variant | 35/63 | NM_000051.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152076Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251120Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135702
GnomAD4 exome AF: 0.0000438 AC: 64AN: 1461294Hom.: 0 Cov.: 31 AF XY: 0.0000413 AC XY: 30AN XY: 726958
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152076Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74280
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Uncertain:5
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The ATM p.Arg1730Gln variant was not identified in the literature nor was it identified in the Genesight-COGR, Cosmic, and LOVD 3.0 (not available). The variant was identified in dbSNP (ID: rs373789346) “With Uncertain significance allele”, ClinVar (classified uncertain significance by GeneDx, Ambry Genetics and Invitae), Clinvitae (3x), and in control databases in 5 of 276816 chromosomes at a frequency of 0.00002 increasing the likelihood that this may be a low frequency benign variant in certain populations of origin (Genome Aggregation Consortium Feb 27, 2017), being identified in the following population: European Non-Finnish in 5 of 126368 chromosomes (frequency: 0.00004). The p.Arg1730 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the Gln variant impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and 1 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jun 10, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 15, 2024 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1730 of the ATM protein (p.Arg1730Gln). This variant is present in population databases (rs373789346, gnomAD 0.004%). This missense change has been observed in individual(s) with breast cancer and chronic lymphocytic leukemia (PMID: 28652578, 30287823). ClinVar contains an entry for this variant (Variation ID: 127402). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (Invitae). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Mar 10, 2020 | - - |
Hereditary cancer-predisposing syndrome Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Nov 07, 2022 | This missense variant replaces arginine with glutamine at codon 1730 of the ATM protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been performed for this variant. This variant has been reported in several case-control studies. In a large international cohort, this variant was reported in 4/60466 breast cancer cases and 3/53461 controls (OR=1.179, 95%CI 0.264 to 5.268; PMID: 33471991). In a study conducted in Japan, this variant was identified in 4/7051 women affected with breast cancer and 1/11241 controls (OR=6.378, 95%CI 0.6 to 313.6; PMID: 30287823). In a case-control study of chronic lymphocytic leukemia, this variant was found in 1/644 cases and 4/8916 controls (PMID: 28652578). This variant has also been reported in an individual affected with ovarian and endometrial cancer (PMID: 30093976). This variant was identified in 5/282500 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Aug 25, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 31, 2023 | The p.R1730Q variant (also known as c.5189G>A), located in coding exon 34 of the ATM gene, results from a G to A substitution at nucleotide position 5189. The arginine at codon 1730 is replaced by glutamine, an amino acid with highly similar properties. This alteration has been reported in 1/110 Asian patients with multiple malignancies who underwent testing for hereditary cancer predisposition in a patient with a personal history of ovarian and endometrial cancers (Chan GHJ et al. Oncotarget, 2018 Jul;9:30649-30660). This alteration has also been reported with a carrier frequency of 4 in 7,051 unselected breast cancer patients and 1 in 11,241 female controls of Japanese ancestry (Momozawa Y et al. Nat Commun, 2018 10;9:4083). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Oct 18, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Mar 15, 2024 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with breast, ovarian, or other cancers, but also in unaffected controls (PMID: 28652578, 30093976, 30287823, 32980694, 36243179); This variant is associated with the following publications: (PMID: 28652578, 28481359, 22071889, 29642553, 30287823, 30093976, 31422574, 33176972, 32980694, 36746516, 36243179, 35534704) - |
Familial cancer of breast Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 30, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Jul 13, 2021 | ACMG classification criteria: PM2 moderate - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 14, 2022 | Variant summary: ATM c.5189G>A (p.Arg1730Gln) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 251120 control chromosomes (gnomAD). In addition, the variant was also reported in 13 heterozygotes from about 38,000 healthy Japanese individuals (in the jMorp database, PMID: 33179747). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.5189G>A has been reported in the literature in individuals affected with different types of cancers, including breast and/or ovarian cancer (Tiao_2017, Jiang_2018, Chan_2018, Momozawa_2018, Neeb_2021), however it was also found in controls (Momozawa_2018) and in non-cancer related cohorts (e.g. Kraemer_2019). Furthermore, the variant was reported in 1/7325 European American women, who are older than age 70 years, and who have never had cancer (in the FLOSSIES database). These reports do not provide unequivocal conclusions about association of the variant with Breast Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Nine other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014, and all of them classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Ataxia-telangiectasia syndrome;C0346153:Familial cancer of breast Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 04, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at